{"id":396350,"date":"2023-12-22T10:13:36","date_gmt":"2023-12-22T15:13:36","guid":{"rendered":"https:\/\/platohealth.ai\/bms-opdualag-faces-discontinuation-may-threaten-future-of-lag-3-inhibitors-in-crc\/"},"modified":"2023-12-26T08:36:18","modified_gmt":"2023-12-26T13:36:18","slug":"bms-opdualag-faces-discontinuation-may-threaten-future-of-lag-3-inhibitors-in-crc","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/bms-opdualag-faces-discontinuation-may-threaten-future-of-lag-3-inhibitors-in-crc\/","title":{"rendered":"BMS’ Opdualag faces discontinuation, may threaten future of LAG-3 inhibitors in CRC","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"

<\/p>\n

\n
\n
\n Share this article<\/p>\n

<\/span>\n <\/div>\n

<\/p><\/div>\n

<\/p>\n<\/div>\n

<\/p>\n

<\/p>\n

\n
\n
\n \n <\/div>
BMS is reshaping the clinical landscape via acquisitions and clinical development. Credit: Photon photo via Shutterstock.<\/figcaption><\/figure>\n<\/div>\n

<\/p>\n

<\/p>\n

On 15 December 2023, Bristol Myers Squibb<\/a> (BMS) announced the discontinuation of the Phase III RELATIVITY-123 trial evaluating the efficacy and safety of Opdualag as a treatment for previously treated, microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients. <\/p>\n

Based on a planned analysis conducted by an independent data committee, the trial was terminated due to futility as it was unlikely for the immune checkpoint inhibitor (ICI) combination to meet the trial\u2019s primary endpoints, which are overall survival (OS) in PD-L1 positive patients and OS in the intent-to-treat population. <\/p>\n

This termination is BMS\u2019 first recent setback in CRC and it adds a layer of uncertainty about the future of LAG-3 inhibitors. Opdualag\u2019s competition, MSD and Keytruda, are now the latest leaders in the immunotherapy race towards gaining approval as a treatment for the vast MSS mCRC patient population.<\/p>\n

BMS has recently been making progress in expanding its market penetration into the mCRC market despite the fact that the landscape will remain challenging in the near future. <\/p>\n

In 2018, BMS first entered the CRC space with its ICI combination of Opdivo and Yervoy, securing a second-line label in the population of microsatellite instability-high (MSI-H) patients, which only makes up approximately 15% of all mCRC patients. <\/p>\n

Through recent external acquisitions and in-house clinical development, BMS is reshaping the CRC treatment landscape. <\/p>\n

\n

Access the most comprehensive Company Profiles
\n on the market, powered by GlobalData. Save hours of research. Gain competitive edge.<\/p>\n